TITLE:
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

CONDITION:
Hepatitis C

INTERVENTION:
Albuferon

SUMMARY:

      This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety,
      tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to
      respond to previous interferon alfa therapy.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Major Inclusion Criteria:

          -  Have a clinical diagnosis of chronic HEP C established on the basis of detectable
             viral load, as measured by a serum HCV RNA test during the screening period.

          -  Have previously failed to respond to treatment with any interferon alfa (IFNa)
             product

          -  Have compensated liver disease with the following minimum criteria: white blood cell
             count > 3,000/mm3, absolute neutrophil count (ANC) > 2,000/mm3, platelets >
             125,000/mm3, and hemoglobin (Hb) > 13 g/dL for males or > 12 g/dL for females.

        Major Exclusion Criteria:

          -  Evidence of decompensated cirrhosis or portal hypertension.

          -  Pregnant or lactating female.

          -  History of any other medical disease or condition that would make the subject (in the
             opinion of the investigator) unsuitable for the study.

          -  A current drug or alcohol addiction
      
